Influence of genetic variants of imatinib on pharmacokinetics and recurrence-free survival in postoperative patients with gastrointestinal stromal tumor

The study investigated imatinib pharmacogenetics and monitoring in 116 postoperative GIST patients to optimize personalized therapy. Imatinib plasma concentrations stabilized by the third month of treatment. Genetic polymorphisms in ABCG2, SLC22A1, and SLC22A5 (OCTN2) were associated with concentration variability. Notably, specific SLC22A5 genotypes (CG/CC) exhibited longer recurrence-free survival and lower disease progression risk. These results inform optimal concentration monitoring and personalized dosing.